Revista da Associacao Medica Brasileira (1992)
-
Rev Assoc Med Bras (1992) · Sep 2021
The efficiency of a mixed exercise program on quality of life and fatigue levels in patients with breast cancer.
Exercise is a nonpharmacological supportive therapy which has been specifically identified to reduce postoperative complications or adverse events of cancer or treatments. Although there are few studies combining resistance and aerobic exercise in cancer survivors, exercise programs are very rare in different places in the literature. This study aims to investigate the effects of mixed-type exercise in different venues on weight, body mass index, fatigue, and quality of life in cancer survivors. ⋯ Our results show that a mixed (fitness center and home) 12-week exercise program provides an improvement in general health and reduces the side effects of the treatments and fatigue in patients with breast cancer. For a good prognostic process after medical treatment, exercise can be recommended in every accessible area.
-
Rev Assoc Med Bras (1992) · Sep 2021
Risk factors for radiological hip involvement in patients with ankylosing spondylitis.
Our study aimed to explore the potential risk factors for radiological hip joint involvement in patients with ankylosing spondylitis (AS). ⋯ The potential risk factors for radiological hip joint involvement were juvenile onset, lower BMI, and bone mass below the expected range for age. Furthermore, continuous NSAID use was the protective factor for radiological hip joint involvement in these population.
-
Rev Assoc Med Bras (1992) · Sep 2021
Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents.
Patients being treated with anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents were reported to have better prognosis related to COVID-19. We evaluated the factors affecting the frequency, clinical course, and outcome of COVID-19 in patients treated with anti-TNF-alpha agents. ⋯ We concluded that the patients treated with anti-TNF-alpha agents having COVID-19 might have mild clinical course and better prognosis.